Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase NA 1Phase 2/3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 11Breast Neoplasms 10Stomach Neoplasms 8Prostatic Neoplasms 7Squamous Cell Carcinoma of Head and Neck 4Lung Neoplasms 4Gastrointestinal Neoplasms 3Neoplasms 2Head and Neck Neoplasms 2HER2-positive Breast Cancer 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Stage I Prostate Adenocarcinoma AJCC v7 1Squamous Cell Non-small Cell Lung Cancer 1Recurrent Squamous Cell Lung Carcinoma 1Recurrence 1Progression Free Survival 1Pathologic Complete Response 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Neoplasm Recurrence, Local 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Lymphoid Interstitial Pneumonia 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1HER2-negative Breast Cancer 1FGFR1 Gene Amplification 1

Interventions

Tamoxifen 1Letrozole 1Lapatinib 1Goserelin 1Epirubicin 1Doxorubicin 1Docetaxel 1Cyclophosphamide 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Breast Diseases × Docetaxel × Clear all
NCT03373708 2017-12-18

Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer

Shandong Cancer Hospital and Institute

Phase 2/3 Unknown
200 enrolled
Breast

Breast Diseases, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡